Table 2.
Distribution of treatment administered by hospital type.
| Overall n, % | UMMC n, % | UMSC n, % | Adjusted OR (95% CI) a | |
|---|---|---|---|---|
| Surgery b | ||||
| Overall | ||||
| No | 285 (8.1%) | 233 (9.8%) | 52 (4.6%) | |
| Yes | 3240 (91.9%) | 2152 (90.2%) | 1088 (95.4%) | 0.88 (0.43–1.79) c |
| Type of surgery * | ||||
| Yes, mastectomy | 2412 (74.4%) | 1644 (76.4%) | 768 (70.6%) | |
| Yes, breast conserving surgery | 824 (25.4%) | 508 (23.6%) | 316 (29.0%) | |
| Yes, unknown | 4 (0.1%) | 0 | 4 (0.4%) | |
| Radiotherapy b | ||||
| Overall | ||||
| No | 1204 (37.9%) | 850 (38.7%) | 354 (36.2%) | |
| Yes | 1970 (62.1%) | 1347 (61.3%) | 623 (63.8%) | 0.83 (0.70–0.99) d |
| Unknown | 351 | 188 | 163 | |
| By surgical status | ||||
| Yes, after breast conserving surgery * | 694 (84.2%) | 443 (87.2%) | 251 (79.4%) | |
| Yes, after mastectomy * | 1263 (52.4%) | 893 (54.3%) | 370 (48.2%) | |
| Yes, with no surgery | 13 (4.6%) | 11 (4.7%) | 2 (3.8%) | |
| Chemotherapy | ||||
| Overall | ||||
| No | 1421 (36.7%) | 1003 (36.4%) | 418 (37.4%) | |
| Yes | 2451 (63.3%) | 1751 (63.6%) | 700 (62.6%) | 1.18 (0.99–1.40) e |
| Unknown | 94 | 13 | 81 | |
| By stage | ||||
| Yes, stage I–III * | 2182 (61.9%) | 1521 (63.8%) | 661 (58.0%) | |
| Yes, stage IV | 268 (61.8%) | 229 (60.9%) | 39 (67.2%) | |
| Yes, stage unknown | 1 (12.5%) | 1 (14.3%) | 0 | |
| Type of chemotherapy regime *,f | ||||
| 1st generation (CMF) | 55 (2.6%) | 48 (3.1%) | 7 (1.2%) | |
| 2nd generation (anthracycline-based) | 1616 (76.4%) | 1295 (83.7%) | 321 (56.6%) | |
| 3rd generation (taxane-based) | 444 (21.0%) | 205 (13.2%) | 239 (42.2%) | |
| Unknown | 336 | 203 | 133 | |
| Hormone therapy | ||||
| Overall | ||||
| No | 1243 (36.0%) | 919 (37.4%) | 324 (32.7%) | |
| Yes | 2208 (64.0%) | 1540 (62.6%) | 668 (67.3%) | 0.90 (0.77–1.06) g |
| Unknown | 515 | 308 | 207 | |
| By ER status | ||||
| Yes, ER positive * | 1982 (88.0%) | 1366 (88.8%) | 616 (86.3%) | |
| Yes, ER negative * | 176 (11.9%) | 137 (13.1%) | 39 (9.2%) | |
| Yes, ER status unknown | 50 | 37 (20.4%) | 13 (22.0%) |
* Statistically significant (p < 0.001); a Derived using a multivariable logistic regression model with the respective treatment as outcome (yes vs. no); b Excluding patients with stage IV breast cancer or unknown stage; c Includes 3525 patients with stage I to stage III breast cancer. Adjusted odds ratio of receiving surgery in UMMC to UMSC. Model was adjusted for ethnicity, tumor size (cm), number of involved axillary nodes, and estrogen and progesterone receptor status; d Includes 3174 patients with known adjuvant radiotherapy status. Adjusted odds ratio of receiving adjuvant radiotherapy in UMMC to UMSC. Model was adjusted for tumor size (cm) and number of involved axillary nodes; e Includes 3872 patients with known chemotherapy status. Adjusted odds ratio of receiving chemotherapy in UMMC to UMSC. Model was adjusted for age, tumor size (cm), number of involved axillary nodes and distant metastasis (yes vs. no); f Includes 2451 patients who received chemotherapy; g Includes 3451 patients with known hormone therapy status. Adjusted odds ratio of hormone therapy in UMMC to UMSC. Model was adjusted for tumor size (cm), number of involved axillary nodes and distant metastasis (yes vs. no). CMF = Cyclophosphamide, Methotrexate, 5-Fluorouracil, ER = Estrogen Receptor.